Pursuant to Regulation 30 and 47 of SEBI Listing Regulations, please find enclosed the copies of newspaper advertisement published on July 2, 2022 in Financial Express (English Language) and Vijayavani (Kannada Language), in compliance with Ministry of Corporate Affairs Circular No. 20/2020 dated May 5, 2020 and Circular No. 2/2022 dated May 5, 2022, intimating that 44th Annual General Meeting of the Company will be held on Thursday, July 28, 2022 at 3.30 pm (IST) through Video Conferencing / Other Audio Visual Means. The above information will also be available on the website of the Company at www.biocon.com.
Pursuant to the declaration of final dividend by the Board of Directors of the Company at its Board Meeting held on April 28, 2022, the Company has sent the enclosed email communication to its shareholders, with respect to the deduction of tax at source on Final Dividend for the Financial Year 2021-22, whose email addresses are registered with the Company/Depository Participants. The specimen of the communication is appended herewith for your reference and records, and the same will also be available on the website of the Company at www.biocon.com.
The Company will organize an Earnings Conference Call for analysts/investors on Thursday, July 28, 2022. The details of the same will be available on the Company's website closer to the scheduled event.
Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, July 27, 2022, inter alia, to approve and take on record the un-audited standalone and consolidated financial results for the quarter ended June 30, 2022. The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading ('the Code') of the Company, has been closed from July 1, 2022 to July 29, 2022 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations, 2015. Accordingly, the trading window will open on July 30, 2022.
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2022 ,inter alia, to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2022, amongst other matters.
With reference to our earlier letter dated April 28, 2022, we wish to inform you that the Board of Directors vide resolution passed through circulation on June 30, 2022 have approved for the change of date of 44th Annual General Meeting (AGM) of the Company from Friday, July 29, 2022 to Thursday, July 28, 2022. Accordingly, the 44th AGM of the Company will be held on Thursday, July 28, 2022 at 3:30 P.M. (IST) through Video Conferencing / Other AudioVisual Means (OAVM). A copy of the Notice convening the said AGM will be sent in due course. Kindly take the above information on record and acknowledge.
Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Company has entered into an agreement for the purpose of acquisition of solar power by acquiring equity stake up to 26% in AMPYR Renewable Energy Resources Eleven Private Limited (AREREPL),a Special Purpose Vehicle formed for generation and supply of solar power.
This is with reference to your email dated June 21, 2022, seeking clarification with regards to the media report titled, 'Biocon subsidiary caught offering bribe to waive off trial of new drug'. In this regard, please note that the Company vide its letter dated June 21, 2022, has submitted the Company Statement issued by Biocon Biologics, to the stock exchanges. The aforesaid letter is attached herewith for reference. The Company has always ensured that all material information is disclosed under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'). We confirm that there is no unpublished price sensitive information available with the Company and there is no information that is material and not disclosed to the stock exchanges. We are cautious of the regulatory provisions and will be informing the stock exchanges of any such event as per the materiality policy of our company.